Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 679137, 14 pages
Review Article

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders

1Department of Bioscience & Biotechnology, Konkuk University, Seoul 143-701, South Korea
2Department of Microbiology, Changwon National University, Changwon 641-773, South Korea
3Department of Biology, Chungnam National University, Daejeon 305-764, South Korea

Received 6 October 2007; Revised 21 December 2007; Accepted 28 February 2008

Academic Editor: Anne Miller

Copyright © 2008 Min-Chul Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Overweight and obesity lead to an increased risk for metabolic disorders such as impaired glucose regulation/insulin resistance, dyslipidemia, and hypertension. Several molecular drug targets with potential to prevent or treat metabolic disorders have been revealed. Interestingly, the activation of peroxisome proliferator-activated receptor (PPAR), which belongs to the nuclear receptor superfamily, has many beneficial clinical effects. PPAR directly modulates gene expression by binding to a specific ligand. All PPAR subtypes ( and ) are involved in glucose metabolism, lipid metabolism, and energy balance. PPAR agonists play an important role in therapeutic aspects of metabolic disorders. However, undesired effects of the existing PPAR agonists have been reported. A great deal of recent research has focused on the discovery of new PPAR modulators with more beneficial effects and more safety without producing undesired side effects. Herein, we briefly review the roles of PPAR in metabolic disorders, the effects of PPAR modulators in metabolic disorders, and the technologies with which to discover new PPAR modulators.